Debating Curative Therapies for Sickle Cell Disease: Gene Therapy vs Allogeneic Transplant-Debating Curative Therapies for Sickle Cell Disease: Gene Therapy vs Allogeneic Transplant

Video Transcription

Video Summary

The speaker reviewed curative treatment options for sickle cell disease, focusing on allogeneic stem cell transplant and gene therapy. She began with a brief overview of sickle cell disease as the most common inherited blood disorder in the U.S., caused by a single beta-globin mutation that leads to hemolysis, vaso-occlusion, and multi-organ damage. She emphasized that despite supportive care and disease-modifying drugs such as hydroxyurea, L-glutamine, and others, median survival remains in the 40s, showing that current therapies have not changed life expectancy substantially.<br /><br />For allogeneic transplant, she noted that HLA-identical sibling donors offer excellent outcomes, especially in children, but only a minority of patients have such a donor. Unrelated donor transplants had poor feasibility because of high chronic graft-versus-host disease. Haploidentical transplant has improved outcomes and expanded access, but risks remain, including graft failure, infections, and chronic GVHD.<br /><br />She then explained gene therapy and gene editing, highlighting the role of fetal hemoglobin and BCL11A suppression. Current gene-editing approaches aim to reactivate fetal hemoglobin by disrupting BCL11A regulation. She reviewed recent trials of Casgevy (exagamglogene autotemcel), Reni-cel, and BEAM-101, showing high rates of VOC-free survival, improved hemoglobin levels, reduced hemolysis, and durable engraftment. However, limitations include the need for myeloablative conditioning, fertility risk, lengthy treatment timelines, high cost, and limited long-term data.<br /><br />Her conclusion: for patients with symptomatic sickle cell disease, both transplant and gene therapy should be discussed through shared decision-making. Gene therapy is especially appealing because it avoids donor dependence and GVHD, but long-term outcomes and broader eligibility remain important unanswered questions.

Keywords

sickle cell disease

allogeneic stem cell transplant

gene therapy

gene editing

BCL11A suppression

fetal hemoglobin

haploidentical transplant

Casgevy

myeloablative conditioning

shared decision-making